Berlin, Germany – February 21, 2026 – Health authorities in the United Kingdom have issued warnings regarding two popular weight loss medications, Ozempic and Wegovy, citing a rare but serious potential side effect: vision loss. The alerts, initially reported by the Daily Telegraph and subsequently echoed across international news outlets, highlight growing concerns about the safety profile of these drugs, which belong to a class known as GLP-1 receptor agonists. This development comes on the heels of another warning linking these medications to a potentially fatal pancreatic condition, and has already impacted the market value of the manufacturer, Novo Nordisk.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has determined that semaglutide, the active chemical ingredient in both Ozempic and Wegovy, may increase the risk of a condition called non-arteritic anterior ischemic optic neuropathy (NAION). NAION can cause sudden, painless vision loss in one eye, and is thought to be caused by a disruption of blood flow to the optic nerve. The MHRA’s warning emphasizes that this side effect is rare, but potentially devastating.
These medications have gained widespread popularity not only for managing type 2 diabetes, but also as a weight loss aid, leading to increased demand and, heightened scrutiny of their potential adverse effects. The recent warnings have prompted a reevaluation of the risk-benefit profile of these drugs, particularly given their expanding leverage beyond their originally intended purpose.
Understanding the Risks: NAION and Semaglutide
Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition characterized by a blockage of blood flow to the optic nerve, leading to sudden vision loss. While the exact cause of NAION is often unknown, certain risk factors have been identified, including high blood pressure, diabetes, and cardiovascular disease. The MHRA’s concern stems from the potential for semaglutide to exacerbate these risk factors or directly contribute to the development of NAION.
The drugs are administered via weekly injection. The mechanism by which semaglutide might contribute to NAION is not fully understood, but experts theorize it could involve changes in blood vessel function or increased inflammation. Patients experiencing sudden vision changes while taking Ozempic or Wegovy are urged to seek immediate medical attention.
Pancreatic Concerns Add to Safety Profile Questions
The vision loss warning is not the first safety concern raised regarding GLP-1 receptor agonists. Just a week prior, the MHRA issued another alert linking these medications to a potential risk of pancreatitis, an inflammation of the pancreas that can be life-threatening in severe cases. This dual warning has raised questions about the overall safety profile of this class of drugs and prompted a closer look at their potential long-term effects.
According to reports, the recent safety concerns have already had a financial impact on Novo Nordisk, the manufacturer of Ozempic and Wegovy. The company’s share price experienced a significant drop following the release of the MHRA’s warnings, reflecting investor anxieties about potential liabilities and decreased demand. Novo Nordisk reported a projected decline in sales of these injections this year, amidst increasing competition from the drug Mounjaro.
Beyond Ozempic and Wegovy: The GLP-1 Class Under Scrutiny
Ozempic and Wegovy are part of a broader class of medications known as GLP-1 receptor agonists. These drugs operate by mimicking the effects of a natural hormone called glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels and promotes feelings of fullness. Other medications in this class include liraglutide (Saxenda) and dulaglutide (Trulicity). The recent warnings regarding Ozempic and Wegovy have prompted calls for a comprehensive review of the safety profiles of all GLP-1 receptor agonists.
The increasing use of GLP-1 agonists for off-label weight loss has also raised ethical concerns. These medications are approved for use in individuals with type 2 diabetes or obesity, but their popularity has led to shortages and increased costs, potentially limiting access for those who need them most. The long-term effects of using these drugs for weight loss are still largely unknown.
Scurvy Concerns and Nutritional Deficiencies
Recent reports, including coverage from Al-Khalij newspaper, have highlighted an unexpected side effect linked to the use of weight loss medications: an increased risk of scurvy, a disease caused by vitamin C deficiency. This is thought to be due to the appetite-suppressing effects of the drugs, leading to reduced dietary intake of essential nutrients. Scurvy, historically associated with long sea voyages and inadequate nutrition, is now being observed in patients taking these medications, prompting doctors to advise monitoring for symptoms like fatigue, bleeding gums, and joint pain.
What Should Patients Do?
Individuals currently taking Ozempic or Wegovy who experience any sudden changes in vision should immediately consult with their healthcare provider. We see crucial to report any symptoms, even if they seem mild, to ensure prompt diagnosis and treatment. Patients should also discuss their individual risk factors with their doctor to determine if these medications are appropriate for them.
The MHRA advises that patients should not stop taking their medication without first consulting with their doctor. Abruptly discontinuing these drugs can lead to uncontrolled blood sugar levels and other complications. Healthcare professionals are encouraged to carefully assess the risks and benefits of these medications on a case-by-case basis, and to provide patients with comprehensive information about potential side effects.
Key Takeaways
- The UK’s MHRA has issued warnings about Ozempic and Wegovy, linking them to a rare risk of vision loss (NAION).
- These medications are also associated with a potential risk of pancreatitis.
- The active ingredient, semaglutide, is under scrutiny for its potential impact on blood vessel function and inflammation.
- Patients experiencing vision changes or symptoms of pancreatitis while taking these drugs should seek immediate medical attention.
- Recent reports suggest a link between these medications and an increased risk of scurvy due to reduced nutrient intake.
The situation remains fluid as health authorities continue to monitor the safety of these medications. Further research is needed to fully understand the mechanisms underlying these adverse effects and to develop strategies for mitigating the risks. The MHRA is expected to provide updated guidance as new information becomes available. Patients and healthcare providers are encouraged to stay informed about the latest developments and to prioritize patient safety.
The next step in this evolving situation will be the release of a comprehensive safety review by the European Medicines Agency (EMA) in March 2026, which is expected to provide further insights into the risks and benefits of GLP-1 receptor agonists. We will continue to provide updates as they become available. Share your thoughts and experiences in the comments below, and please share this article with anyone who may be affected by these important health warnings.